formation Set (HEDIS) 5 and the Diabetes Quality Improvement Project (DQIP) 6 there is no clinical quality measure set in general national use. About 4 years ago, the Health Care Financing Administration (HCFA) began to implement a program to measure and track the quality of the care for which Medicare pays. Simultaneously, HCFA committed to using its peer review organization (PRO) contractors to systematically promote improved performance on the quality measures tracked under this program using a voluntary, collaborative, and nonpunitive educational strategy. 7 This article describes the 24 initial measures used in this program and reports the baseline values measured in 1997-1999. The Medicare measurement system we developed includes most of the HEDIS clinical measures, but it addresses more conditions, measures more elements of care, and measures the care delivered to the 85% of Medicare beneficiaries who are covered under FFS. The sampling frame provides statelevel results to target PRO activities, evaluate PRO and HCFA effectiveness in improving care, and create a national picture of care under Medicare FFS.
Even though purchasers and beneficiaries are primarily interested in outcomes, we focused on measuring processes of care critical to outcomes rather than on measuring outcomes themselves. Five reasons drove this choice: (1) in comparison to outcomes of care, there is more consensus on appropriate processes of care and the target rates (nearly 100%); (2) measuring processes of care generally does not require the risk adjustment that has been so controversial in comparisons of outcomes; (3) it is easier for providers, practitioners, and plans to identify and fix the reasons why critical processes of care were not carried out than to determine why outcomes are not optimal; (4) many important outcomes take years; and (5) because significant, achievable improvements in outcomes are generally much smaller in relative terms than improvements in processes, unrealistic sample sizes are necessary to measure significant improvements in outcomes. While we report only process measures here, HCFA intends to track outcomes, riskadjusted when possible, at the national level for the targeted conditions.
METHODS

Clinical Topic and Measure Selection
The clinical topics were selected using 5 criteria: (1) the disease is prevalent and a major source of morbidity or mortality in the Medicare population; (2) there is strong scientific evidence and practitioner consensus that there are processes of care that can substantially improve outcomes; (3) reliably measuring the delivery of these processes is feasible; (4) there is a substantial "performance gap" between current performance and desirable performance; and (5) there is at least anecdotal evidence that PROs can intervene effectively to improve performance on the measures. Using these criteria, we adopted or developed 24 process-of-care measures (TABLE 1) relating to primary prevention, secondary prevention, or treatment of acute myocardial infarction (AMI), breast cancer, diabetes mellitus, heart failure, pneumonia, and stroke.
Measures
Each measure is based on professionally developed, widely accepted practice guidelines that were translated into measures either as part of a larger partnership (HEDIS and DQIP) or national public health surveillance effort (Behavioral Risk Factor Surveillance System [BRFSS]) or by HCFA staff in consultation with experts and relevant professional groups. Whenever possible, we used measures that have wide acceptance and have been used and tested. The detailed measure specifications and the scientific evidence supporting each of these measures is summarized on the HCFA Web site. Acute Myocardial Infarction. We updated and/or expanded measures that had been used for the Medicare Cooperative Cardiovascular Project. 9, 10 Heart Failure. We created measures based on treatment recommendations from the American College of Cardiology/American Heart Association and the Agency for Healthcare Research and Quality, which were reviewed by clinical expert technical advisory panels and extensively field tested by PROs.
Stroke. We adapted measures based on treatment recommendations from the American College of Chest Physicians, the American Heart Association, the National Stroke Association, and the American Academy of Neurology; the measures were reviewed by clinical expert technical advisory panels and extensively field tested by PROs.
Treatment of Pneumonia. We used measures developed in collaboration with the American Thoracic Society, the Infectious Diseases Society of America, and the Centers for Disease Control and Prevention; the measures were reviewed by clinical expert technical advisory panels and extensively field tested by PROs.
Prevention of Pneumonia. We used outpatient immunization measures in the BRFSS, which correspond both to the HEDIS system and to commitments that HCFA has made to Congress under the Government Performance and Results Act and inpatient measures corresponding to recommendations of the Advisory Committee on Immunization Practices.
Breast Cancer. We adopted the breast cancer screening measure used in HEDIS, 5 which measures the percentage of women aged 52 to 69 years who have received a mammogram in the past 2 years.
Diabetes. We selected those measures developed by the DQIP that can be computed from claims data. Indicators based on chart abstraction were not included because a representative sample of office records is not currently available to PROs.
Data Sources and Sampling Frame
In all measures except immunization status, the denominator or sampling frame is patients enrolled in FFS Medicare, and Medicare+Choice (managed care) plan members are excluded. All states in the United States were sampled, plus the District of Columbia and Puerto Rico.
Inpatient Measures (AMI, Heart Failure, Atrial Fibrillation, Stroke, Treatment of Pneumonia). We sampled from Medicare hospital claims data in each state for each condition. The discharges were eligible for selection only if the principal diagnosis met the criteria for the target condition, except for stroke prevention, for which we accepted any diagnosis of atrial fibrillation. We sampled the discharges for a 6-month period within each state. For a third of the states, this period was from April to October 1998; for another third of the states, July to December 1998; and for the remaining states, October 1998 to March 1999. We sampled up to 850 discharges for AMI, pneumonia, and stroke, and up to 900 discharges for heart failure and used a census of all discharges for states with fewer than the targeted number of discharges during the period. The universe of eligible claims was first sorted by age, race, sex, and hospital, and cases were then sampled systematically from a random starting point. Data for the performance measures were ). The estimates therefore differ from those for other samples by including beneficiaries who are enrolled in managed care and excluding persons younger than 65 years old. Rate estimates reported here are from the 1997 survey. Screening for or administration of influenza and pneumococcal vaccine for inpatients with pneumonia was ascertained from nursing and physician notes and other information in the medical record.
Breast Cancer (Mammography). The denominator was all women aged 52 to 69 years who were enrolled in Medicare FFS in both 1997 and 1998. Whether a mammogram had been performed in the 2 years was determined by whether Medicare had paid a claim for a diagnostic or screening mammogram in that period.
Diabetes. The denominator was all FFS beneficiaries aged 18 to 75 years who had 2 outpatient claims or 1 inpatient claim with a diagnosis of diabetes mellitus during a 1-year period starting January 1998-July 1998, with the start date determined by the date when the PRO's contract began in that state. Whether a service had been provided was determined by whether Medicare had paid a claim for the service.
Statistical Methods
For the inpatient measures, patients found to have a clinical contraindication to the process of care were either included as having received appropriate care (heart failure measures) or excluded from both the numerator and denominator (other appropriateness of care measures). Reliability was calculated as the percentage agreement on an indicator for 2 blinded, independent abstractions at different abstraction centers. Performance was calculated at the state level for each of the measures. For 22 measures, results were calculated as the percentage of patients receiving appropriate care; for time to angioplasty or thrombolytic therapy, the result was calculated as the median number of minutes from arrival at the hospital to beginning of angioplasty or thrombolytic agent instillation. We primarily direct our attention to variation among states (including the District of Columbia and Puerto Rico). We therefore calculated, for each measure, performance of the median state rather than a national average. We also calculated the rank of each state on each performance measure and then calculated the average rank for each state across the 22 measures (we excluded time to angioplasty and time to thrombolytic therapy from this calculation because the sample size was too small in many states) and the SD of the 22 ranks for each state. We mapped the distribution of average ranks to display geographic patterns.
RESULTS
Across the 4 inpatient conditions we obtained 94.3% to 99.2% of sampled records (median, 95.3%). The reliability of measures based on medical record abstraction ranged from 80% to 95% with a median interrater reliability of 90%. TABLE 2 shows the number of charts in the denominator of each rate in 2 ways: the individual rate or time number is formatted in a type that reflects the number of charts used; the Table also provides the median number of charts across all states. Even though more than 700 records were obtained for each condition in most states, the number of patients who qualified for a particular indicator was rarely even half that number and sometimes much less. Table 2 shows 3 kinds of results: (1) the performance of the median state on each measure, (2) the average of each state's performance ranks across the 22 measures, and (3) the rank of each state among all states based on this average rank. More detailed results are available at the HCFA Web site. 8 The performance rates in the median state for each of the 22 rate measures range from a high of 95% (avoidance of sublingual nifedipine in acute stroke) to a low of 11% (patients with pneumonia screened for pneumococcal immunization status before discharge). When performance indicators are ranked by the rate in the median state, the median performance is 69% (patients discharged with heart failure diagnosis who received angiotensinconverting enzyme inhibitors; diabetic patients having an eye examination in the last 2 years). The range of rates for each measure also varies widely across the states, from a low of a 13-percentage point range for avoidance of sublingual nifedipine for patients with acute stroke (Nevada, 86%; Wyoming, 100%) to a high of a 54-percentage point range for antibiotic administered within 8 hours of hospital arrival to patients with an admission diagnosis of pneumonia (Puerto Rico, 38%; Montana, 93%). The median of the ranges for performance indicators (other than time to angioplasty and thrombolytic therapy) is 33 percentage points and the median interquartile range is 8 percentage points. Table 2 shows the performance of each state on each quality measure. New Hampshireof these rankings; these averages of rankings range from 10 to 48 because no state is consistently at the top or bottom. Based on the average of the rankings, Table 2 shows the state's rank among all states and areas (range, 1-52).
The FIGURE shows that the rankings tend to follow a geographic pattern with northern and less populous states more likely to rank high than southern and more populous states.
COMMENT Implications
Previous studies have reported results using some of the individual measures reported here, [1] [2] [3] [4] 10 and HEDIS provides a picture (albeit more limited) of care in Medicare managed care, but we believe that this is the first study to provide a broad picture of quality of care in FFS Medicare and the first to include data that have been verified by chart abstraction of a national sample for several conditions. This study provides strong evidence of a substantial opportunity to improve the care delivered to Medicare beneficiaries. Available data suggest that providing the services measured here could each save hundreds to thousands of lives a year, but more precise estimates of the effect of such improvement on beneficiary health are beyond the scope of this study.
The differences in average performance among states and regions are modest compared with the overall need for improvement. Nevertheless, the data suggest real underlying geographic differences in the way care is delivered to the Medicare FFS population. They also suggest that variations among states on individual measures are part of a larger pattern and not simply local variation. We do not yet understand the reasons for these differences or whether aspects of the systems in high-performing states can be easily replicated in lowperforming states.
Limitations and Qualifications
These measures give a somewhat unbalanced picture of Medicare services. They overrepresent inpatient and preventive services, underrepresent ambulatory care, and scarcely represent interventional procedures at all.
This article is generally limited to care delivered in FFS Medicare. Nationally, about 85% of Medicare beneficiaries are cared for under FFS and about 15% under managed care, but in Arizona, California, Florida, and Pennsylvania more than 25% of beneficiaries are enrolled in managed care. Comparing HEDIS data from managed care with this FFS data presents technical problems that we have not yet solved because denominators and/or measure definitions differ in the 2 systems. However, the data reported here for FFS do not differ dramatically from the HEDIS data reported for Medicare managed care. 13 This article is limited to national-and state-level information. Information on individual practitioners and providers requires a different and more efficient data collection and reporting system designed to collect such voluminous data. Even with practitioner-and providerlevel data, many practitioners and providers treat too few patients with particular conditions to generate a meaningful sample size, and it will remain difficult to determine which practitioner is responsible for delivering the process of care that is measured.
We must also consider the extent to which these measures fairly represent quality of care for the services and population addressed. There are 2 concerns: the validity of the measures as representations of quality of care and the accuracy of the data.
Each of the measures is based on both strong science and professional consensus that delivering the service would either improve outcomes or be necessary to services that would improve outcomes. Nevertheless, for almost all of the services, there are circumstances in which delivering them would be inappropriate. For the inpatient measures, we included the major contraindications in our abstraction and computational algorithms, but there are likely to be unusual circumstances that account for a few cases of undelivered care. The measures are designed to credit care as appropriate if there is doubt, and we know from PRO field experience with the measures that valid, unmeasured contraindications are not frequent.
Small numbers are a problem for some inpatient measures, such as time to angioplasty and thrombolytic therapy, because a relatively small number of the beneficiaries in our sample received these services in some states. However, the effect of small denominators is to increase the variation among states, not to bias the median downward. We use surveys for influenza and pneumococcal immunization rates because many influenza immunizations are delivered without claims being submitted to Medicare, and because there is no immediately feasible way to accurately determine pneumococcal immunization status from existing Medicare claims data files. Surveys, of course, may have recall and sampling bias, but this does not appear to be a major problem for the other measures.
If interrater reliability is 90%, the accuracy of the individual abstractor is about 95% (each rater accounts for about half of disagreements between raters). The range of reliabilities is about 80% to 95%, suggesting that, even for the most unreliable measure, abstraction errors would not account for a performance level below 90%.
Future Steps
We believe that this article and the tracking system behind it establish a mechanism for HCFA to move beyond its historical focus on individual cases and providers and to take responsibility as a purchaser for the care delivered to the population of Medicare beneficiaries. Although it is customary to speak of holding providers, practitioners, and health plans accountable for the care they provide, it is at least as important to hold purchasers, whether Medicare or Medicaid or commercial or government employers, accountable for the quality of the care they purchase, because they are making continual and important decisions that potentially balance quality against expenditures. As required by the Government Performance and Results Act, HCFA is beginning to assume this responsibility by reporting some of these measures to Congress as part of its annual budget submission.
HCFA intends to extend the Medicare clinical performance tracking system in 3 ways. First, for those measures based on medical record abstraction, we are now collecting a continuous sample large enough to provide accurate trending of national data every few months, although too small to provide state-level estimates more than every few years. Second, we will collect enough data to make accurate state-level estimates every 3 years (synchronous with PRO contract cycles). This will allow us to evaluate the success of each PRO in meeting its major contractual requirement, which is to improve statewide performance on the measures. Third, we will extend the system to include other settings, such as nursing homes, home health agencies, and other providers and to include other clinical priorities.
Obviously, pervasive gaps between what is being done and what could be done invite us to consider what policies might lead to improvements. A future article will describe the quality improvement strategy that HCFA is pursuing to improve performance on these and other measures. Recent reports 3, 4 have emphasized the importance of focusing on system failure rather than practitioner failure to working to close these performance gaps. The United States has poured enormous resources into practitioner training and very little into improving processes in the systems within which those practitioners work, and it is time to redress that balance. Available evidence suggests that, at least for preventive services, systems changes are more effective than either provider or patient education in improving provision of services. 14 The data should also remind us of the need for partnership among HCFA, beneficiaries, practitioners, providers, and health plans to achieve improvements. The HCFA PROs are charged with promoting improvement. They now have performance-based contracts with more than $200 million a year for improving performance on the measures reported. Their contracts hold them accountable for successful promotion of improvement, and there is good evidence that they can contribute to significant improvement in care. 10 Nevertheless, neither HCFA nor PROs deliver care. They can only provide technical assistance to practitioners, providers, and plans; take steps that will make it easier for practitioners and providers to deliver and for beneficiaries to receive needed care; and serve as conveners for partnerships among local stakeholders. Only practitioners and providers can make such systems changes as putting appropriate standing orders in place, installing failure-resistant information systems, and designing processes that deliver critical services within the optimum window of time. Segmenting improvement efforts according to payment source is inefficient and counterproductive. Partnerships among all of the stakeholders, regardless of source of payment, can make improvement possible and are urgently needed. 
